Labeling Changes Possible For HCV Direct-Acting Antivirals As EMA Probes HBV Reactivation
This article was originally published in SRA
Executive Summary
The European Medicines Agency has begun a review of the direct-acting antivirals (DAAs) for hepatitis C in light of a number of recent cases showing that hepatitis B virus has been reactivated in some HCV patients treated with the newer products1.
You may also be interested in...
EMA Committee Urges Warning About Hep B Reactivation In Patients Taking DAAs
The European Medicines Agency’s pharmacovigilance committee wants manufacturers of the direct-acting antivirals for hepatitis C to include a warning about the possibility of hepatitis B reactivation in patients who carry both viruses.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.